CN103083274A - 一种含左旋米那普仑的缓释组合物及其制备方法 - Google Patents
一种含左旋米那普仑的缓释组合物及其制备方法 Download PDFInfo
- Publication number
- CN103083274A CN103083274A CN2013100618156A CN201310061815A CN103083274A CN 103083274 A CN103083274 A CN 103083274A CN 2013100618156 A CN2013100618156 A CN 2013100618156A CN 201310061815 A CN201310061815 A CN 201310061815A CN 103083274 A CN103083274 A CN 103083274A
- Authority
- CN
- China
- Prior art keywords
- acrylic resin
- hypromellose
- release
- preparation
- handed midalcipran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 229960000600 milnacipran Drugs 0.000 title claims abstract description 74
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000004925 Acrylic resin Substances 0.000 claims abstract description 51
- 229920000178 Acrylic resin Polymers 0.000 claims abstract description 51
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 51
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 51
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 49
- 239000000463 material Substances 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims description 69
- 229960003943 hypromellose Drugs 0.000 claims description 36
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 22
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 16
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 16
- 239000000945 filler Substances 0.000 claims description 16
- 239000003002 pH adjusting agent Substances 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 14
- 238000013268 sustained release Methods 0.000 claims description 12
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 11
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 11
- 229950005770 hyprolose Drugs 0.000 claims description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- 239000003232 water-soluble binding agent Substances 0.000 claims description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 7
- 239000012730 sustained-release form Substances 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920000609 methyl cellulose Polymers 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- 235000010981 methylcellulose Nutrition 0.000 claims description 5
- 239000010409 thin film Substances 0.000 claims description 5
- 238000005550 wet granulation Methods 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 238000009501 film coating Methods 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 235000011132 calcium sulphate Nutrition 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 27
- 230000006399 behavior Effects 0.000 abstract description 14
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 12
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract description 11
- 210000004051 gastric juice Anatomy 0.000 abstract description 9
- 239000004480 active ingredient Substances 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 78
- 238000000034 method Methods 0.000 description 42
- 239000008363 phosphate buffer Substances 0.000 description 41
- 239000003814 drug Substances 0.000 description 40
- 239000012530 fluid Substances 0.000 description 32
- 239000008187 granular material Substances 0.000 description 24
- 229940079593 drug Drugs 0.000 description 23
- 238000002156 mixing Methods 0.000 description 23
- 239000003826 tablet Substances 0.000 description 23
- 230000002496 gastric effect Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 238000005469 granulation Methods 0.000 description 11
- 230000003179 granulation Effects 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 9
- 238000011978 dissolution method Methods 0.000 description 9
- 238000010348 incorporation Methods 0.000 description 9
- 238000005070 sampling Methods 0.000 description 9
- 235000021355 Stearic acid Nutrition 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- -1 hydroxypropyl Chemical group 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229920003091 Methocel™ Polymers 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 239000013563 matrix tablet Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000004531 microgranule Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 229920003105 Methocel™ A15 LV Polymers 0.000 description 1
- XNCDYJFPRPDERF-PBCQUBLHSA-N Milnacipran hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1C[NH3+] XNCDYJFPRPDERF-PBCQUBLHSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229960000638 milnacipran hydrochloride Drugs 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003361 porogen Substances 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310061815.6A CN103083274B (zh) | 2012-09-04 | 2012-09-04 | 一种含左旋米那普仑的缓释组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310061815.6A CN103083274B (zh) | 2012-09-04 | 2012-09-04 | 一种含左旋米那普仑的缓释组合物及其制备方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201210323131 Division CN102793683B (zh) | 2012-09-04 | 2012-09-04 | 一种含左旋米那普仑的缓释组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103083274A true CN103083274A (zh) | 2013-05-08 |
CN103083274B CN103083274B (zh) | 2014-08-06 |
Family
ID=48196760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310061815.6A Active CN103083274B (zh) | 2012-09-04 | 2012-09-04 | 一种含左旋米那普仑的缓释组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103083274B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1425373A (zh) * | 2003-01-08 | 2003-06-25 | 江苏正大天晴药业股份有限公司 | 苦参素缓释制剂及其制备方法 |
CN1698594A (zh) * | 2005-04-25 | 2005-11-23 | 中国药科大学 | 硫普罗宁的缓释制剂 |
-
2012
- 2012-09-04 CN CN201310061815.6A patent/CN103083274B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1425373A (zh) * | 2003-01-08 | 2003-06-25 | 江苏正大天晴药业股份有限公司 | 苦参素缓释制剂及其制备方法 |
CN1698594A (zh) * | 2005-04-25 | 2005-11-23 | 中国药科大学 | 硫普罗宁的缓释制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN103083274B (zh) | 2014-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101005830B (zh) | 包含普拉克索或其可药用盐的延长释放片剂、其制备方法及用途 | |
CN102438597A (zh) | 一种选自中枢性作用肌弛缓药类型的化合物的新型缓释制剂 | |
RU2013125148A (ru) | Пероральная фармацевтическая таблетка с регулируемым высвобождением месалазина и способ ее получения | |
CN102218042A (zh) | 富马酸喹硫平组合物的缓释片剂及其制备方法 | |
CN109044981A (zh) | 一种普瑞巴林胃漂浮型缓释片及其制备方法 | |
JP2023026623A5 (zh) | ||
CN110420192B (zh) | 一种单硝酸异山梨酯缓释片及制备方法 | |
PT1322158E (pt) | Composições farmacêuticas de libertação prolongada contendo metformina e seu método de produção | |
CN101204387A (zh) | 一种盐酸坦洛新缓释胶囊 | |
CN105012264B (zh) | 丙戊酸钠缓释片及其制备工艺和用途 | |
CN104873473A (zh) | 一种氯化钾缓释片及其制备方法 | |
WO2011072481A1 (zh) | 一种颗粒组合控释片 | |
CN103520169A (zh) | 米氮平片及其制备方法 | |
CN107412198A (zh) | 盐酸度洛西汀肠溶缓释颗粒剂及其制备方法 | |
CN103083274B (zh) | 一种含左旋米那普仑的缓释组合物及其制备方法 | |
CN102793683B (zh) | 一种含左旋米那普仑的缓释组合物及其制备方法 | |
CN101164532A (zh) | 盐酸度洛西汀缓释药物 | |
KR101587140B1 (ko) | 위장관 질환 치료용 모사프리드 구연산염 미니정제 함유 서방성 캡슐 제제 및 이의 제조 방법 | |
CN102283816B (zh) | 西洛多辛缓释片剂及其制备方法 | |
CN101711753B (zh) | 兰索拉唑固体制剂的制备方法 | |
CN102525989B (zh) | 洛索洛芬钠骨架缓释片 | |
CN104840442B (zh) | 一种含有富马酸喹硫平的缓释片剂及其制备方法 | |
CN107744509B (zh) | 枸橼酸莫沙必利片剂及其制备方法 | |
CN106580905A (zh) | 一种他喷他多缓释药物组合物及其制备方法 | |
JP2018508501A (ja) | タムスロシン塩酸塩含有徐放性顆粒を含む経口用薬剤学的製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 33, Xiaxian 1st Village, Meilan District, Haikou City, Hainan Province Patentee after: Hainan Qirong Information Technology Co.,Ltd. Address before: Meilan District of Qingnian Road city of Haikou province Hainan 570311 Xiaxian Village No. 133 Patentee before: HAINAN KANGHONG MEDICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Slow-release composition containing L-milnacipran and preparation method thereof Effective date of registration: 20200528 Granted publication date: 20140806 Pledgee: China Everbright Bank Co.,Ltd. Haikou Branch Pledgor: Hainan Qirong Information Technology Co.,Ltd. Registration number: Y2020980002573 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210701 Granted publication date: 20140806 Pledgee: China Everbright Bank Co.,Ltd. Haikou Branch Pledgor: Hainan Qirong Information Technology Co.,Ltd. Registration number: Y2020980002573 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a sustained-release composition containing l-minapram and a preparation method thereof Effective date of registration: 20210705 Granted publication date: 20140806 Pledgee: China Everbright Bank Co.,Ltd. Haikou Branch Pledgor: Hainan Qirong Information Technology Co.,Ltd. Registration number: Y2021980005697 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230327 Address after: Room 1506, Building B, Jinghai Garden, No. 1, Haidian Island Sandong Road, Haidian Street, Meilan District, Haikou City, Hainan Province, 570100 Patentee after: Ge Yabo Address before: No. 33, Xiaxianyi Village, Meilan District, Haikou City, Hainan Province, 570100 Patentee before: Hainan Qirong Information Technology Co.,Ltd. |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230608 Granted publication date: 20140806 Pledgee: China Everbright Bank Co.,Ltd. Haikou Branch Pledgor: Hainan Qirong Information Technology Co.,Ltd. Registration number: Y2021980005697 |